Skip to main content

Table 1 Basic characteristics and treatment schedules in eligible studies

From: Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

First author Year Design Number of patients Median age (range) Irinotecan Temozolomide Days of each cycle Line of therapy Median number of cycles (range) Total cycles of therapy
Wagner 2007 Retrospective study 16 18 (7–33) 10–20 mg/m2/day on days 1–5 and days 8–12 100 mg/m2/day on days 1–5 every 21–28 days  >  = 2 5 (1–17) 95
Anderson 2008 Retrospective study 25 15 10 mg/m2/day on days 1–5 (or expand to 10 days) 100 mg/m2/day on days 1–5 NA NA 6 NA
Casey 2009 Retrospective study 20 19.5 (2–40) 10–20 mg/m2/day on days 1–5 and days 8–12 100 mg/m2/day on days 1–5 every 21 days  >  = 2 7.5 (1–20) 154
Kurucu 2015 Retrospective study 20 14 (1–18) 20 mg/m2/day on days 1–5 and days 8–12 100 mg/m2/day on days 1–5 every 28 days  >  = 2 14 (7–18) 97
Palmerini 2018 Retrospective study 51 21 (3–65) 40 mg/m2/day on days 1–5 100 mg/m2/day on days 1–5 every 21 days  >  = 1 5 (1–31) NA
Salah 2021 Retrospective study 52 20 (5–45) 40/50 mg/m2/day on days 1–5
or 20 mg/m2/day on days 1–5 and days 8–12
100 mg/m2/day on days 1–5 every 21 days  >  = 2 4 (1–7) 236
  1. Abbreviations: NA Data not available